Frequency and component analysis of contaminants generated in preparation of anticancer agents using closed system drug transfer devices (CSTDs).
Antibodies, Monoclonal
/ adverse effects
Antineoplastic Agents
/ adverse effects
Chemical Safety
/ instrumentation
Drug Compounding
Equipment Contamination
/ prevention & control
Hazardous Substances
/ adverse effects
Health Personnel
Hospitals
Humans
Injections
Japan
Occupational Exposure
/ analysis
Occupational Health
Patient Safety
Protective Devices
Risk Assessment
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
07 01 2022
07 01 2022
Historique:
received:
13
04
2021
accepted:
29
11
2021
entrez:
8
1
2022
pubmed:
9
1
2022
medline:
23
2
2022
Statut:
epublish
Résumé
Occupational exposure of anticancer agents during their preparation has been recognized as a serious hazard. Closed system drug transfer devices (CSTDs) enable "safe" preparation of agents for medical personnel and ensure a safe hospital environment. However, artificial particles of infusion materials have been reported during CSTD use. Here, the incidence of insoluble fine particles during preparation of anticancer agents using CSTDs was examined. Visible insoluble fine particles were found in 465 (9.4%) of 4948 treatment cases at Ehime University Hospital with CSTD use. Contaminants occurred more frequently during preparation of monoclonal antibodies than cytotoxic anticancer agents (19.4% vs. 4.1%, respectively, P < 0.01). A similar survey was conducted at nine hospitals to investigate the incidence of insoluble fine particles with or without CSTDs. Insoluble fine particles were detected in 113 (15.4%) of 732 treatment cases during preparation of monoclonal antibodies with CSTD use. In contrast, the occurrence of insoluble fine particles without CSTDs was found in only 3 (0.073%) of 4113 treatment cases. Contamination with CSTDs might cause harmful effects on patients during cancer therapy. We strongly recommend the use of in-line filters combined with infusion routes after CSTD use to avoid contamination-associated adverse events.
Identifiants
pubmed: 34996936
doi: 10.1038/s41598-021-03780-0
pii: 10.1038/s41598-021-03780-0
pmc: PMC8741972
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antineoplastic Agents
0
Hazardous Substances
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
139Informations de copyright
© 2022. The Author(s).
Références
Arch Environ Health. 1994 May-Jun;49(3):165-9
pubmed: 8185386
Br Med J (Clin Res Ed). 1985 Nov 16;291(6506):1390
pubmed: 3933681
Occup Environ Med. 1994 Apr;51(4):229-33
pubmed: 8199663
J Oncol Pharm Pract. 2011 Mar;17(1):39-48
pubmed: 20156932
J Am Pharm Assoc (Wash). 1999 Mar-Apr;39(2):141-5
pubmed: 10079649
Int Arch Occup Environ Health. 2003 Feb;76(1):5-10
pubmed: 12592576
BMC Nurs. 2010 Sep 16;9:15
pubmed: 20846432
J Pharm Sci. 2020 Jan;109(1):22-29
pubmed: 31697946
J Pharm Sci. 2015 May;104(5):1610-21
pubmed: 25737325
Am J Hosp Pharm. 1976 Jun;33(6):543-6
pubmed: 1274972
J Clin Pharm Ther. 2001 Apr;26(2):87-91
pubmed: 11350530
J Am Pharm Assoc Am Pharm Assoc. 1947 Oct;36(10):289-93
pubmed: 20270085
Lancet. 1979 Jun 9;1(8128):1250-1
pubmed: 87722
J Pharm Sci. 1980 Jul;69(7):755-62
pubmed: 7391933
Med J Aust. 1964 Jul 4;2:1-6
pubmed: 14175312
Int Arch Occup Environ Health. 1992;64(2):105-12
pubmed: 1399019
J Oncol Pharm Pract. 2013 Jun;19(2):99-104
pubmed: 23292973
Br J Ind Med. 1992 Dec;49(12):855-61
pubmed: 1472444
Am J Health Syst Pharm. 2003 Nov 15;60(22):2314-20
pubmed: 14652980
N Engl J Med. 1985 Jan 10;312(2):78-82
pubmed: 3880597
Cancer Treat Rev. 1984 Mar;11(1):39-67
pubmed: 6375862
J Urol. 1979 Aug;122(2):163-4
pubmed: 459006
Am J Hosp Pharm. 1975 Oct;32(10):1001-7
pubmed: 1103617
Am J Health Syst Pharm. 2006 Sep 15;63(18):1736-44
pubmed: 16960258
J Pharm Sci. 2020 Jan;109(1):761-768
pubmed: 31376374
J Pharm Pharmacol. 2017 Oct;69(10):1341-1351
pubmed: 28639328
J Pharm Sci. 2020 Jan;109(1):845-853
pubmed: 31628922
Q J Exp Physiol Cogn Med Sci. 1960 Jul;45:252-64
pubmed: 13834048
Am J Health Syst Pharm. 2002 Jan 1;59(1):68-72
pubmed: 11813470